HER2-positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab-based chemotherapy: A case report.
Fiche publication
Date publication
décembre 2020
Journal
Clinical case reports
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LONGO Raffaele
Tous les auteurs :
Longo R, Legros PO, Talbi M, Wagner M, Paraschiv EA, Campitiello M, Plastino F, Rozzi A
Lien Pubmed
Résumé
This case highlights the rare entity, salivary duct carcinoma (SDC), which is difficult to diagnose and manage. It is the first published case of a metastatic, HER2-positive parotid SDC successfully treated by a dual anti-HER2 treatment associated to a chemotherapy.
Mots clés
HER2, duct carcinoma, parotid, pertuzumab, trastuzumab
Référence
Clin Case Rep. 2020 Dec;8(12):2878-2882